Monoacylglycerol lipase inhibitors, such as the one mentioned, are primarily used in research focused on understanding and treating neurological disorders. These inhibitors target the enzyme monoacylglycerol lipase, which plays a key role in breaking down endocannabinoids in the brain. By inhibiting this enzyme, these compounds help increase the levels of endocannabinoids, which can have therapeutic effects in conditions like epilepsy, chronic pain, and neurodegenerative diseases such as Alzheimer's and Parkinson's. Additionally, they are being explored for their potential in reducing inflammation and managing mood disorders, offering a promising avenue for developing new treatments in neuroscience and psychiatry.